KEAP1 is mutated in 3.18% of malignant solid tumor patients [3].

KEAP1 is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain KEAP1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

KEAP1 is mutated in 12.1% of non-small cell lung carcinoma patients [3].

KEAP1 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KEAP1 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KEAP1 is mutated in 10.9% of squamous cell lung carcinoma patients [3].

KEAP1 is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KEAP1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

KEAP1 is mutated in 2.07% of bladder carcinoma patients [3].

KEAP1 is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KEAP1 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KEAP1 is mutated in 2.48% of ovarian carcinoma patients [3].

KEAP1 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KEAP1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KEAP1 is mutated in 1.52% of glioblastoma patients [3].

KEAP1 is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains KEAP1 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KEAP1 is mutated in 1.37% of colorectal carcinoma patients [3].

KEAP1 is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KEAP1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KEAP1 is mutated in 1.1% of melanoma patients [3].

KEAP1 is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains KEAP1 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KEAP1 is mutated in 1.05% of pancreatic carcinoma patients [3].

KEAP1 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KEAP1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KEAP1 is mutated in 0.96% of breast carcinoma patients [3].

KEAP1 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KEAP1 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KEAP1 is mutated in 0.75% of sarcoma patients [3].

KEAP1 is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KEAP1 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KEAP1 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains KEAP1 status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KEAP1 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains KEAP1 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

KEAP1 is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains KEAP1 status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].